Skip to content

Improving Sensitivity of Urine Cytology for Bladder Cancer

Non-Invasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01826097
Enrollment
0
Registered
2013-04-08
Start date
2013-01-31
Completion date
2013-11-30
Last updated
2018-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Keywords

Cytology, Whole body massage vibration

Brief summary

Can a commercially available vibrating chair increase the number of urothelial cells in a urine sample of healthy participants non-invasively? The investigators plan is participants will alternate 15 minutes of drinking eight fluid ounces of water and 15 minutes of sitting in the vibrating chair for one hour. The control group will alternate 15 minutes of drinking eight fluid ounces of water and 15 minutes of sitting in a non-vibrating chair for one hour. Then, urine samples will be collected and examined for urothelial cell concentration for both groups.

Interventions

DEVICELa-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration

Sponsors

Johns Hopkins University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
SINGLE

Eligibility

Sex/Gender
MALE
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Only adult male subjects who will not have surgery within a period of 2 weeks. * Over the age of 18 * Have had a confirmed diagnosis of stage 0-4 transitional cell carcinoma within the last 30 days

Exclusion criteria

* Cognitive impairment resulting in the inability to give informed consent * Lack of spoken and written English resulting in the inability to give informed consent * Presence of infectious disease * Insulin dependent diabetes mellitus * Endogenous osteosynthetical material implants * Knee or hip prosthesis * Pacemaker * Epilepsy * Musculo-skeletal disorders * Weight in excess of 250 pounds * Poor circulation

Design outcomes

Primary

MeasureTime frameDescription
Number of Cancer Cellsup to 24 weeksNumber of Cancer Cells in a 50 ml Urine

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026